Basit öğe kaydını göster

dc.contributor.authorDemir, Fadime
dc.contributor.authorHasbek, Zekiye
dc.contributor.authorErselcan, Taner
dc.contributor.authorTurgut, Bulent
dc.date.accessioned2020-11-20T14:39:32Z
dc.date.available2020-11-20T14:39:32Z
dc.date.issued2020
dc.identifier.issn2667-663X
dc.identifier.urihttps://doi.org/10.4328/ACAM.20042
dc.identifier.urihttps://hdl.handle.net/20.500.12809/483
dc.descriptionWOS: 000572683400011en_US
dc.description.abstractAim: This study aimed to investigate the role of serum anti-thyroglobulin antibody (anti-TgAb) as a marker to predict the success of radioactive iodine (RAI) ablation therapy in differentiated thyroid cancer (DTC) patients and also investigate the role of anti-TgAb in the follow-up of thyroid cancer. Materials and Methods: One hundred thirteen DTC patients with total thyroidectomy who received RAI ablation therapy enrolled in this retrospective study. The first measurement was performed immediately before ablation therapy (thyroglobulin (Tg)1, anti-TgAb 1). The second measurement was performed just before the whole-body iodine 131 (I-131) scan (WBS) within 6-12 months after ablation (Tg 2, Anti-TgAb 2). Patients were divided into two groups according to ablation success: Group 1 (successful) and Group 2 (unsuccessful). Tg and anti-TgAb levels and the difference between two measurements were compared between groups. Results: In terms of Anti-Tg antibody positivity and the anti-Tg Ab 1 and anti-Tg Ab 2 levels, there was no statistically significant difference between groups (p= 0.661, p = 0.716, p = 0.764, respectively). When the groups were compared in terms of anti-Tg Ab level change after treatment, a statistically significant decrease was observed in Group 1 (p <0.001), but there was no statistically significant decrease in Group 2 (p = 0.277). Discussion: In conclusion, a reduction in anti-Tg Ab level, measured within 6-12 months after the ablation, can be used as an indicator of treatment success.en_US
dc.item-language.isoengen_US
dc.publisherBayrakol Medical Publisheren_US
dc.item-rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAnti-Thyroglobulin Antibodyen_US
dc.subjectThyroglobulinen_US
dc.subjectDifferentiated Thyroid Canceren_US
dc.titleThe role of anti-thyroglobulin antibody in treatment and follow up of differentiated thyroid canceren_US
dc.item-typearticleen_US
dc.contributor.departmenten_US
dc.contributor.departmentTemp[Demir, Fadime] GOP Univ, Fac Med, Dept Nucl Med, Tokat, Turkey -- [Hasbek, Zekiye] Cumhuriyet Univ, Fac Med, Dept Nucl Med, Sivas, Turkey -- [Erselcan, Taner] Mugla Sitki Kocman Univ, Fac Med, Dept Nucl Med, Mugla, Turkey -- [Turgut, Bulent] Izmir Katip Celebi Univ, Dept Nucl Med, Izmir, Turkeyen_US
dc.identifier.doi10.4328/ACAM.20042
dc.identifier.volume11en_US
dc.identifier.issue3en_US
dc.identifier.startpage207en_US
dc.identifier.endpage210en_US
dc.relation.journalAnnals of Clinical and Analytical Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster